AstraZeneca shares jump 5% today; I think they could go higher still this year

Jon Smith notes the jump in the AstraZeneca share price today and thinks that there’s room for it to run higher after full-year results.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A graph made of neon tubes in a room

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As I write, the best performing FTSE 100 stock today is AstraZeneca (LSE:AZN). It currently trades at 8,808p, up just over 5% on the day. The bump comes after the company released successful Phase 3 trial results for a treatment for prostrate cancer. With AstraZeneca shares up 12% over the past year and recent full-year results showing good growth, I think more upside is on the horizon.

Drug and full-year financial results

The short-term rally comes following news that the combination of the Lynparza drug with hormone therapy can delay disease progression by several months. This could have a large commercial use for prostrate cancer going forward. 

Any new drug that solves for or can help lessen the impact of a disease is going to be a positive for a large pharmaceutical company. Some banking analysts think that this particular breakthrough could have revenue implications of several billion pounds. 

This good news comes only a week or so after the release of full-year results for 2021. In it, total revenue increased 41% year-on-year when including Covid-19 vaccine revenue. Even excluding this, revenue rose by 26%. 

Some of this growth was driven by the acquisition and integration of Alexion, but even so, it’s a strong performance. The report noted “double digit growth across all regions”.

Earnings per share (EPS) was down heavily versus last year, but there were valid reasons for this. For example, higher expenses due to investment in its R&D pipeline, along with one-off integration costs with Alexion.

AstraZeneca shares can move higher from here

The results might be in the recent past, but I think the AstraZeneca shares have the impetus to keep going from current levels. One major reason for this is the positive outlook. For the full-year 2022, the business expects “core EPS… to increase by a mid-to-high twenties percentage”. Part of the driver behind this is new Phase 3 rollouts of new medicines, such as the one in the news today.

I do acknowledge that the revenue benefit from Covid-19 vaccines is likely to diminish in 2022 and beyond. Yet there are two aspects to consider here.

Firstly, the virus mutates. Therefore I imagine that several booster jabs will be required, or even an updated general vaccine in the future. Secondly, as shown by the 2021 numbers, the vaccine revenue isn’t make-or-break on the financials for AstraZeneca. It was a profitable business before the pandemic and I think will continue that way going forward.

I think one of the risks for AstraZeneca shares going forward is the comprehensive review that is expected to run through to 2025. In the long term, I think this is good, but over the next year or so it could be tough. This could include high restructuring costs, potential redundancies, and other headlines that could sting in the short term.

Personally, I’m thinking of buying AstraZeneca shares now despite the risks. A strong financial outlook and a good pipeline of medicines should help support an upward move in the share price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jon Smith and The Motley Fool UK have no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 bargain investment trusts with yields over 7% to consider buying for a Stocks & Shares ISA

Roland Head highlights two high-yield opportunities that could deliver attractive returns inside a Stocks and Shares ISA.

Read more »

Investing Articles

How I’m targeting a £10,000 second income from dividend shares

Dividend shares are a great source of extra cash. But Stephen Wright thinks investors looking to finance a comfortable retirement…

Read more »

Investing Articles

A once-in-a-decade chance to buy FTSE shares for passive income!

Even with the market rally, many FTSE shares are trading at dirt cheap valuations, creating a rare opportunity to lock…

Read more »

Investing Articles

Here’s how many Tesco shares I’d need for £200 a month in passive income

Our writer takes a look at Tesco shares to assess whether they seem like a worthwhile option for his dividend…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

At 58p, is Lloyds actually a penny stock? And is it a buy today?

Lloyds continues to trade below a pound, but now that interest rates have surged, will the bank break through this…

Read more »

Investing Articles

£20k in savings? Here’s how much passive income I’d earn from these 7 dividend shares

Charlie Carman explains how he'd target a mighty passive income stream by investing an entire ISA allowance in a diversified…

Read more »

Investing Articles

The Bank of England predicts another stock market correction! Who cares?

Concerns are on the rise as the UK’s central bank anticipates a sharp correction in asset prices. But can investors…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

3 FTSE 100 stock bargains to consider buying right now

There may be a valuation re-rating coming for large-cap FTSE 100 companies, so I'm targeting some of these bargain stocks…

Read more »